Theralase Technologies Inc. V.TLT

Back To The Data…Recap

[CancerSlayer]

From the company's 4/29 interim analysis:

The interim analysis of the Study II Evaluable Patient clinical data (with 3 patients from Study Ib) supports the following provisional conclusions:

Patient Assessment Visit	Evaluable Patients*	Complete Response (“CR”)	Partial Response (“PR”)	Total Response (CR + PR)
90 Days	35	49%	17%	66%
180 Days	30	47%	20%	67%
270 Days	23	39%	9%	48%
360 Days	21	24%	14%	38%
450 Days	21	24%	10%	34%

Note: Evaluable Patients are defined as patients who have evaluable data; hence, have been evaluated by the principal investigator and thus excludes patients who have clinical data pending.

For evaluable patients, who completed Study II, who achieved a CR at 90 days, 78% continue to demonstrate that CR at 180 and 270 days, while 56% continue to demonstrate that CR at 360 and 450 days.

Excluding previous data reports/timelines, here's my simplified breakdown of the potential CR rates (worst to best case scenario) when considering the first 12 vs the remaining 23 (the fully optimized group):


                        Evaluable Patients     Total CRs       First 12 CR       Remaining 23 (# evaluable - 12)       

90 Days                  35                              17                3/12 (25%)        14 of 23 (61%)

180 Days                30                              14                                          11 of 18 (61%) to 14 of 18 (78%)

270 Days                23                               9                                            6 of 11 (55%) to 9 of 11 (82%)

360 Days                21                               5                                            2 of 9 (22%) to 5 of 9 (56%)

450 Days                21                               "                                                            "


Interpretation:  Optimization helps : )

[Johnandrose22]

Outstanding analysis, to date,....thanks so much.

[Eoganacht]

Great post CancerSlayer. In my humble opinion the results of all 125 patients will be much better than the results of the first 25 patients . 

[CancerSlayer]

Agree...& I'm hoping a total of 100 participants will ultimately suffice.  As a longer-term investor, I ignore the daily drama, technicals & near-term volatility, especially when it applies to investing in a promising biotech...unless I'm in the mood for some personal amusement.   To date, we are blowing the single-agent options out of the water right now & that gap

[ScienceFirst]

The FDA is well aware of the BCG shortage and the team of experts that will advice it are all urologists.     Given:   - that we would be the first non-immunotherapy drug that can deliver such results,  - that we are not in combo with BCG, - that we are a standalone treatment, - that we are a only 2 doses treatment, - that we don’t have toxicity, - that we

[Sunvalley]

Your post makes nothing but total sense ScienceFirst. In my way of thinking the only things that can stand in the way of TLT becoming the new SOC in bladder cancer is big pharma,s clout with politics and money both of which could be formidable opponents. Lets hope that common sense overides the nonsense of power and greed in the health sector. I think back to all of the delays and obstacles that

[ScienceFirst]

Market shares is what drives any companies.  Big pharmas or not.  And because there are competition for those market shares between themselves, it's who moves the fastest. So data is key.